Site Title

Literature

• Overview
• Features
• Approved Blood Pool Agents
• Protocols and Sequences
• Clinical Examples
• FAQ
• Literature
• Recent Publications
• Publication Archive
• Books
• Links
• Ask The Expert

Publication Archive

• Port M, Corot C, Violas X, Robert P, Raynal I, Gagneur G (2005). How to compare the efficiency of albumin-bound and nonalbumin-bound contrast agents in vivo: the concept of dynamic relaxivity.
  Invest Radiol 40(9): 565-573
• Caravan P, Amedio JC Jr, Dunham SU, Greenfield MT, Cloutier NJ, McDermid SA, Spiller M, Zech SG, Looby RJ, Raitsimring AM, McMurry TJ, Lauffer RB (2005). When are two waters worse than one? Doubling the hydration number of a Gd-DTPA derivative decreases relaxivity.
  Chemistry 11(20): 5866-5874
• Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ (2005). Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths.
  Invest Radiol 40(11): 715-724
• Goyen M, Edelman M, Perreault P, O'Riordan E, Bertoni H, Taylor J, Siragusa D, Sharafuddin M, Mohler ER 3rd, Breger R, Yucel EK, Shamsi K, Weisskoff RM (2005). MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325.
  Radiology 236(3): 825-833, Epub 2005 Jul 14
• Rapp JH, Wolff SD, Quinn SF, Soto JA, Meranze SG, Muluk S, Blebea J, Johnson SP, Rofsky NM, Duerinckx A, Foster GS, Kent KC, Moneta G, Middlebrook MR, Narra VR, Toombs BD, Pollak J, Yucel EK, Shamsi K, Weisskoff RM (2005). Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography--multicenter comparative phase III study.
  Radiology 236(1): 71-78
• Zhang Y, Choyke PL, Lu H, Takahashi H, Mannon RB, Zhang X, Marcos H, Li KC, Kopp JB (2005). Detection and localization of proteinuria by dynamic contrast-enhanced magnetic resonance imaging using MS325.
  J Am Soc Nephrol 16(6): 1752-1757. Epub 2005 May 4
• Tombach B, Reimer P (2005). Soluble paramagnetic chelates and stabilized colloidal particle solutions of iron oxides as contrast agents for magnetic resonance imaging.
  Curr Med Chem 12(23): 2795-2804
• Kobayashi H, Brechbiel MW (2005). Nano-sized MRI contrast agents with dendrimer cores.
  Adv Drug Deliv Rev 57(15): 2271-2286. Epub 2005 Nov 10
• Thompson MK, Misselwitz B, Tso LS, Doble DM, Schmitt-Willich H, Raymond KN (2005). In vivo evaluation of gadolinium hydroxypyridonate chelates: initial experience as contrast media in magnetic resonance imaging.
  J Med Chem 48(11): 3874-3877
• Yancy AD, Olzinski AR, Hu TC, Lenhard SC, Aravindhan K, Gruver SM, Jacobs PM, Willette RN, Jucker BM (2005). Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling.
  J Magn Reson Imaging 21(4): 432- 442

• Zhou X, Caravan P, Clarkson RB, Westlund PO (2004).
  On the philosophy of optimizing contrast agents. An analysis of 1H NMRD profiles and ESR lineshapes of the Gd(III)complex MS-325+HSA.
  J Magn Reson 167(1): 147-160
• Sirlin CB, Vera DR, Corbeil JA, Caballero MB, Buxton RB, Mattrey RF (2004).
  Gadolinium-DTPA-dextran: a macromolecular MR blood pool contrast agent.
  Acad Radiol 11(12): 1361-1369
• Tombach B, Reimer P, Bremer C, Allkemper T, Engelhardt M, Mahler M, Ebert W, Heindel W (2004)
  First-pass and equilibrium-MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): results of a human pilot study.
  NMR Biomed 17(7): 500-506
• Preda A, Novikov V, Moglich M, Turetschek K, Shames DM, Brasch RC, Cavagna FM, Roberts TP (2004).
  MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer.
  J Magn Reson Imaging 20(5): 865-873
• Edelman RR (2004).
  Contrast-enhanced MR imaging of the heart: overview of the literature.
  Radiology 232(3): 653-668. Epub 2004 Jul 29
• Dewey M, Kaufels N, Laule M, Schnorr J, Raynaud JS, Hamm B, Taupitz M (2004).
  Magnetic resonance imaging of myocardial perfusion and viability using a blood pool contrast agent.
  Invest Radiol 39(8): 498-505
• Ersoy H, Jacobs P, Kent CK, Prince MR (2004).
  Blood pool MR angiography of aortic stent-graft endoleak.
  AJR Am J Roentgenol 182(5): 1181-1186

• Perreault P, Edelman MA, Baum RA, Yucel EK, Weisskoff RM, Shamsi K, Mohler ER 3rd (2003).
  MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial.
  Radiology 229(3): 811-820. Epub 2003 Oct 30
• Jerosch-Herold M, Hu X, Murthy NS, Rickers C, Stillman AE (2003).
  Magnetic resonance imaging of myocardial contrast enhancement with MS-325 and its relation to myocardial blood flow and the perfusion reserve.
  J Magn Reson Imaging 18(5): 544-554.
• Lei T, Udupa JK, Odhner D, Nyul LG, Saha PK (2003).
  3DVIEWNIX-AVS: a software package for the separate visualization of arteries and veins in CE-MRA images.
  Comput Med Imaging Graph 27(5): 351-362
• Weinmann HJ, Ebert W, Misselwitz B, Schmitt-Willich H (2003).
  Tissue-specific MR contrast agents.
  Eur J Radiol 46(1): 33-44
• Daldrup-Link H, Brasch RC(2003).
  Macromolecular contrast agents for MR mammography: current status.
  Eur Radiol 13(2): 354-365. Epub 2002 Oct 31
• Corot C, Violas X, Robert P, Gagneur G, Port M (2003).
  Comparison of different types of blood pool agents (P792, MS325, USPIO) in a rabbit MR angiography-like protocol.
  Invest Radiol 38(6): 311-319

• Svensson J, Leander P, Maki JH, Stahlberg F, Olsson LE (2002).
  Separation of arteries and veins using flow-induced phase effects in contrast-enhanced MRA of the lower extremities.
  Magn Reson Imaging. 2002 Jan; 20(1): 49-57
• Sharafuddin MJ, Stolpen AH, Dang YM, Andresen KJ, Roh BS (2002).
  Comparison of MS-325- and gadodiamide-enhanced MR venography of iliocaval veins.
  J Vasc Interv Radiol 13(10): 1021-1027
• Lei T, Udupa JK, Saha PK, Odhner D, Baum R, Tadikonda SK, Yucel EK (2002).
  3D MRA visualization and artery-vein separation using blood-pool contrast agent MS-325.
  Acad Radiol 9 Suppl 1: S127-133.
• Kraitchman DL, Chin BB, Heldman AW, Solaiyappan M, Bluemke DA (2002).
  MRI detection of myocardial perfusion defects due to coronary artery stenosis with MS-325.
  J Magn Reson Imaging 15(2): 149-158

• Lahti KM, Lauffer RB, Chan T, Weisskoff RM (2001).
  Magnetic resonance angiography at 0.3 T using MS-325.
  MAGMA 12(2-3): 88-91
• Caravan P, Comuzzi C, Crooks W, McMurry TJ, Choppin GR, Woulfe SR (2001).
  Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging.
  Inorg Chem 40(9): 2170-2176
• Bluemke DA, Stillman AE, Bis KG, Grist TM, Baum RA, D'Agostino R, Malden ES, Pierro JA, Yucel EK (2001).
  Carotid MR angiography: phase II study of safety and efficacy for MS-325.
  Radiology 219(1): 114-122

• Saeed M, Wendland MF, Higgins CB (2000).
  Blood pool MR contrast agents for cardiovascular imaging.
  J Magn Reson Imaging 12(6): 890-898
• Luk-Pat GT, Gold GE, Olcott EW, Hu BS, Nishimura DG (1999).
  High resolution three-dimensional in vivo imaging of atherosclerotic plaque.
  Magn Reson Med 42: 762-771
• Knopp MV, von Tengg-Kobligk H, Floemer F, Schoenberg SO (1999).
  Contrast agents for MRA: future directions.
  J Magn Reson Imaging 10(3): 314-316
• Lauffer RB, Parmelee DJ, Dunham SU, Ouellet HS, Dolan RP, Witte S, McMurry TJ, Walovitch RC (1998)
  MS-325: Albumin-targeted contrast agent for MR angiography.
  Radiology 207(2): 529-538